18F-FDG PET/CT指导高危金黄色葡萄球菌菌血症治疗时长
该回顾性研究纳入36例高危金黄色葡萄球菌菌血症但超声心动图和18F-FDG PET/CT均无转移感染征象的患者,与40例无并发症菌血症患者比较,两组治疗时长相近(15.9 vs 15.4天),病例组无SAB相关死亡,复发1例,提示基于18F-FDG PET/CT指导的2周静脉治疗可能安全。
要点
- 高危SAB无转移感染征象者,18F-FDG PET/CT指导的短疗程治疗可能安全。
- 病例组与对照组治疗时长相近,SAB相关死亡和复发率低。
- 18F-FDG PET/CT可用于个体化决定高危SAB治疗时长。
核心结论
- 高危SAB无心内膜炎且18F-FDG PET/CT无转移感染征象时,2周静脉治疗可能是安全的。
研究设计与样本
- 回顾性分析2013至2017年2个医疗中心收治的SAB患者,病例组为有并发症危险因素但超声心动图正常且18F-FDG PET/CT无转移感染征象者(36例),对照组为无并发症菌血症者(40例)。
主要发现
- 两组治疗时长相似(15.9 vs 15.4天)。
- 病例组无SAB相关死亡,对照组1例;病例组复发1例,对照组2例。
- 总体死亡率两组无差异(19.4% vs 15.0%,P=0.64)。
临床怎么用
- 对高危SAB患者,若超声心动图正常且18F-FDG PET/CT无转移感染征象,可考虑缩短静脉抗生素疗程至约2周。
局限性
- 回顾性研究,样本量较小(36例病例和40例对照)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current guidelines recommend intravenous antibiotic therapy for at least 4 wk in patients with high-risk Staphylococcus aureus bacteremia (SAB), because of the risk for metastatic infection. We evaluated the safety of a shorter duration of treatment in patients with high-risk SAB without signs of metastatic infection at presentation, using standard 18F-FDG PET/CT and echocardiography. Methods: Retrospective analyses were performed of patients with SAB admitted between 2013 and 2017 in 2 medical centers. Patients with risk factors for complicated bacteremia (community acquisition, persistently positive blood cultures, >72 h of fever, or foreign body materials present), a normal echocardiography result, and 18F-FDG PET/CT without signs of metastatic infection were included (cases) and compared with patients with uncomplicated bacteremia (absence of any of the risk factors and no known metastatic disease, controls). Primary outcomes were 3-mo SAB-specific mortality rate and recurrent infection. The secondary outcome was overall mortality. Results: We included 36 cases and 40 controls. Both groups had a similar treatment duration (15.9 vs. 15.4 d). No deaths occurred as a consequence of SAB in the cases, compared with 1 in the control group. One relapse occurred in the case group and 2 in the control group. Overall mortality did not differ between the groups (19.4% vs. 15.0%, P = 0.64). Conclusion: This study suggests that intravenous treatment for 2 wk in high-risk patients with SAB without endocarditis and absence of metastatic infection on 18F-FDG PET/CT is safe. A diagnostic-driven approach using 18F-FDG PET/CT to determine treatment duration in high-risk SAB seems feasible and allows tailoring treatment to individual patients.
引用
- Berrevoets MAH, Kouijzer IJE, Slieker K, et al. 18F-FDG PET/CT-Guided Treatment Duration in Patients with High-Risk Staphylococcus Aureus Bacteremia: A Proof of Principle. J Nucl Med. 2018. PMID: 30552202. doi:10.2967/jnumed.118.221929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。